1. Home
  2. TTEK vs VRTX Comparison

TTEK vs VRTX Comparison

Compare TTEK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tetra Tech Inc.

TTEK

Tetra Tech Inc.

HOLD

Current Price

$34.53

Market Cap

8.6B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$452.25

Market Cap

96.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTEK
VRTX
Founded
1966
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
96.6B
IPO Year
1991
1991

Fundamental Metrics

Financial Performance
Metric
TTEK
VRTX
Price
$34.53
$452.25
Analyst Decision
Buy
Buy
Analyst Count
5
25
Target Price
$43.25
$494.64
AVG Volume (30 Days)
2.7M
1.4M
Earning Date
01-28-2026
11-03-2025
Dividend Yield
0.75%
N/A
EPS Growth
N/A
N/A
EPS
0.93
14.22
Revenue
$4,617,360,000.00
$11,723,300,000.00
Revenue This Year
N/A
$11.01
Revenue Next Year
$6.70
$8.74
P/E Ratio
$37.16
$31.78
Revenue Growth
6.84
10.33
52 Week Low
$27.27
$362.50
52 Week High
$42.98
$519.68

Technical Indicators

Market Signals
Indicator
TTEK
VRTX
Relative Strength Index (RSI) 52.43 59.92
Support Level $33.27 $433.81
Resistance Level $35.60 $463.85
Average True Range (ATR) 0.88 10.71
MACD -0.04 0.51
Stochastic Oscillator 66.25 72.53

Price Performance

Historical Comparison
TTEK
VRTX

About TTEK Tetra Tech Inc.

Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: